Invesco Reports 5.3% Of LivaNova Shares Held By Its Adviser Clients

Invesco reported voting authority over most of the position, while adviser clients receive dividends and sale proceeds.

Share
Invesco Reports 5.3% Of LivaNova Shares Held By Its Adviser Clients

Invesco reported a 5.3% position in LivaNova, which makes medical devices for heart surgery and neurological conditions, in a passive ownership disclosure filed with the SEC Tuesday. The shares are held by its investment-adviser clients, and Invesco certified that the holding was not intended to change or influence LivaNova's control.

Clients Hold The Economic Rights

The position totaled 2,928,425 common shares as of September 30, 2026. Invesco reported sole voting authority over 2,913,963 shares and sole authority to sell or otherwise dispose of the entire reported position.

The clients are entitled to the dividends and proceeds from share sales. No individual person has more than 5% economic ownership of the reported securities.

Invesco is the parent holding company of investment advisers including Invesco Advisers and Invesco Capital Management LLC. Its role as their parent is the basis for counting the clients' shares as its beneficial ownership—the ownership attributed to it for securities-disclosure purposes.

Heart Surgery And Nerve Stimulation

LivaNova's Cardiopulmonary business sells heart-lung machines and oxygenators, along with equipment for recovering patients' blood and tubing and cannulae used during heart surgery.

Its Neuromodulation business sells the VNS Therapy System. The implanted device stimulates the left vagus nerve to treat drug-resistant epilepsy and difficult-to-treat depression. The company is also testing a sleep apnea device.

LivaNova reaches hospitals and other healthcare providers, including perfusionists, neurologists and neurosurgeons, through sales representatives, agents and distributors. It sells in more than 100 countries. In 2025, the U.S. accounted for 53% of net revenue, Europe for 19% and the rest of the world for 28%.

LivaNova had a market value of $5.1 billion as of 5:08 p.m. ET Tuesday.

Sources

More on LivaNova

All LivaNova (LIVN) coverage →